Hansoh Pharmaceutical Group Past Earnings Performance
Past criteria checks 5/6
Hansoh Pharmaceutical Group has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 5.5% per year. Hansoh Pharmaceutical Group's return on equity is 16.9%, and it has net margins of 39%.
Key information
9.4%
Earnings growth rate
7.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 5.5% |
| Return on equity | 16.9% |
| Net Margin | 39.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Hansoh Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 12,098 | 4,714 | 4,316 | 2,364 |
| 31 Mar 24 | 11,101 | 3,996 | 4,278 | 2,231 |
| 31 Dec 23 | 10,104 | 3,278 | 4,241 | 2,097 |
| 30 Sep 23 | 9,782 | 2,926 | 4,207 | 1,990 |
| 30 Jun 23 | 9,459 | 2,575 | 4,172 | 1,884 |
| 31 Mar 23 | 9,421 | 2,579 | 4,160 | 1,789 |
| 31 Dec 22 | 9,382 | 2,584 | 4,148 | 1,693 |
| 30 Sep 22 | 9,675 | 2,652 | 4,266 | 1,771 |
| 30 Jun 22 | 9,968 | 2,720 | 4,385 | 1,849 |
| 31 Mar 22 | 9,952 | 2,717 | 4,378 | 1,823 |
| 31 Dec 21 | 9,935 | 2,713 | 4,371 | 1,797 |
| 30 Sep 21 | 9,524 | 2,675 | 4,199 | 1,630 |
| 30 Jun 21 | 9,112 | 2,638 | 4,027 | 1,463 |
| 31 Mar 21 | 8,901 | 2,603 | 3,945 | 1,358 |
| 31 Dec 20 | 8,690 | 2,569 | 3,862 | 1,252 |
| 30 Sep 20 | 8,377 | 2,526 | 3,751 | 1,146 |
| 30 Jun 20 | 8,063 | 2,483 | 3,641 | 1,039 |
| 31 Mar 20 | 8,373 | 2,520 | 3,843 | 1,080 |
| 31 Dec 19 | 8,683 | 2,557 | 4,044 | 1,121 |
| 30 Sep 19 | 8,615 | 2,357 | 4,158 | 1,099 |
| 30 Jun 19 | 8,548 | 2,157 | 4,271 | 1,077 |
| 31 Mar 19 | 8,135 | 2,030 | 4,135 | 979 |
| 31 Dec 18 | 7,722 | 1,903 | 3,999 | 881 |
| 31 Dec 17 | 6,186 | 1,595 | 3,318 | 576 |
| 31 Dec 16 | 5,433 | 1,476 | 2,916 | 403 |
Quality Earnings: 3KY has high quality earnings.
Growing Profit Margin: 3KY's current net profit margins (39%) are higher than last year (27.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 3KY's earnings have grown by 9.4% per year over the past 5 years.
Accelerating Growth: 3KY's earnings growth over the past year (83.1%) exceeds its 5-year average (9.4% per year).
Earnings vs Industry: 3KY earnings growth over the past year (83.1%) exceeded the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: 3KY's Return on Equity (16.9%) is considered low.